Dr. Duncan on the Expansion of CAR T-Cell Therapy

Video

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Since its inception in B-cell acute lymphoblastic leukemia (ALL), it is exciting to see CAR T-cell therapy expand to other malignancies and patient populations, says Duncan. It is also encouraging to see products being developed that target more than CD19, as patients with CD19-targeted disease treated with CD19-directed CAR T-cell therapy ultimately relapse with CD19-negative disease. Now, there are data showing that CAR T cells can be used to target both CD19 and CD22.

Beyond that, there's a population of patients who have relapsed T-cell ALL, who until recently, were unable to receive CAR T-cell therapy, says Duncan. Those patients have a poor survival rate after relapse of approximately 28% or less. It's exciting to see CAR T-cell studies developing and expanding to include very high-risk patient populations. In keeping with the current pace of progress, investigators are hopeful that CAR T-cell therapy will expand to entirely new populations.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.